Certara.R School - Lesson 12: History and Advantages of the PML Language
Pinnacle 21 Enterprise
Unlocking Efficiency and Quality: What is New in Phoenix™️ 8.4?
What’s New for SEND 2023 Webinar
AI in Healthcare Today – Dell Technologies & Certara
Vyasa Layar Explainer
Certara SEND Webinar Series Session #1
FDA Modernization Act 2.0 – What does it mean for drug developers?
D360 as your organization’s extendable and central data engine
Machine learning model selection with Darwin in Pirana
Learn how Certara’s Integral streamlines PK/PD workflows
Learn how to leverage the power of cloud computing to streamline your workflow!
Learn how to create CDISC domains in minutes with PK Submit
How to Define & Measure Clinical Endpoints to Optimize Your Oncology Drug Dosing
Learn how to leverage the power of cloud computing to streamline your workflow!
Phoenix WinNonlin Secure
Learn how to shorten the drug discovery design-make-test-analyze cycle with D360
Learn how to save valuable time on PK/PD analysis and modeling with Certara’s Phoenix Platform
Learn how to streamline PK/PD workflows with Certara’s Integral Data Repository
Learn why Phoenix is the industry gold standard for PK/PD analysis
eChalk Talk: How Oncology Drug Developers Can Prepare for FDA’s Project Optimus
BaseCase Video Control Demo
Learn how Integral streamlines PK/PD workflows & ensures compliance with regulatory requirements
1. Phoenix Screen Resolution
Improved Workflow and Expanded Functionality of RsNLME - Version 1
What Oncology Drug Developers Should Expect from the FDA’s Project Optimus
Predicting and Taming Immunogenicity: Overview of Immunogenicity & ADA Assays
Predicting and Taming Immunogenicity: What is an Integrated Summary of Immunogenicity (ISI)?
Predicting and Taming Immunogenicity: Complex Biologic Considerations
Best Practices in Data Programming: A Chat with Susan Potts
The TOGETHER Study Shows that Fluvoxamine Reduces Risk of Prolonged Hospitalization
Predicting and Taming Immunogenicity: Strategies for your Biologic Drug
Learn How Discovery Data Technology Enables Faster Discovery Research
New Horizons in Pediatric Drug Development - Day 2, Session 2 - Panel Discussion
New Horizons in Pediatric Drug Development - Day 2, Session 3
New Horizons in Pediatric Drug Development - Day 2, Session 3 - Panel Discussion
New Horizons in Pediatric Drug Development - Day 2, Session 3
New Horizons in Pediatric Drug Development - Day 2, Session 3
New Horizons in Pediatric Drug Development - Day 2, Session 2
New Horizons in Pediatric Drug Development - Day 2, Session 2
New Horizons in Pediatric Drug Development - Day 2, Session 2
New Horizons in Pediatric Drug Development - Day 2, Session 1 - Panel Discussion
New Horizons in Pediatric Drug Development - Day 2, Session 1
New Horizons in Pediatric Drug Development - Day 2, Session 1
New Horizons in Pediatric Drug Development - Day 2 - Opening Remarks
New Horizons in Pediatric Drug Development - Day 1, Session 2 - Panel Discussion
New Horizons in Pediatric Drug Development - Day 1, Session 2, Part 2
New Horizons in Pediatric Drug Development - Day 1, Session 2, Part 1
New Horizons in Pediatric Drug Development - Day 1, Session 2 - Panel Discussion
New Horizons in Pediatric Drug Development - Day 1, Session 1, Part 2
New Horizons in Pediatric Drug Development - Day 1, Session 1, Part 1
New Horizons in Pediatric Drug Development - Day 1 Q&A
New Horizons in Pediatric Drug Development - Keynote
New Horizons in Pediatric Drug Development - Day 1 - Introduction & Welcome
Better Together: An Interview with Patrick Smith, Raj Bhardwaj, and Mayumi Hasegawa
What does the Clin Pharm Plan for a Biologic Look Like?
Pharmacometrics & Clinical Pharmacology FOMO: Why the Future of Research is in Africa
When you have a spot, get your spot!
Your First Choice in Complex Biologics Drug Development
The Wizard of Oligos: There’s no place like having a successful drug development program!
The Promises and Pitfalls of Gene Therapy for Rare Diseases
Sealing Pharma Commercialization Deals: Creating Optimal Value for Investors
Best Practices for oligonucleotide therapeutic development: Q&A
Oligonucleotide therapeutic development: Clinical pharmacology considerations
Oligonucleotide therapeutic development: Pre-clinical and translational considerations
What are oligonucleotide therapeutics, and how do they work?
Expert Tips for Pediatric Drug Development and Regulatory Success
Getting the Dose Right for COVID-19 Vaccines
Submerge in the Oligonucleotide Emerge: Best Practices for Developing These Complex Biologics
How to Accelerate COVID-19 Vaccine Development with Biosimulation
Enhance Your Drug Development Capacity with Clin Pharm Study Execution & Operational Support
Model-based meta-analysis for comparative efficacy and safety of therapeutics for COVID-19
Making your drug program investor-ready
Avoid these common mistakes to secure a deal
An Introduction to Asset Evaluation
The Role of MIDD in Drug Development for COVID-19
Juvenile toxicity studies considerations – not just “mini” general tox!
Supporting the global approval of an antiviral drug for infants
Intro to Smart In Silico Tools to Aid in Translating In Vitro & In Vivo Studies
Accelerating Medicines & Vaccines Using Virtual Patients
Solving a Mystery Using PBPK: How Drug-excipient Complexes Can Confound a Metabolic DDI Result
CODEx Demo
Fostering Pediatric Oncology Drug Development
Accelerating Therapeutics for COVID-19: Dr. Craig Rayner
D360 Overview
Accelerating Vaccine Development: Applications to COVID-19 and Future Pandemics
HIV Déjà Vu? Optimizing Cocktail Therapies for COVID-19
COVID-19 Therapeutic Considerations for Children and Pregnant Women
Team Certara - Let's Beat COVID Together
Using PK/PD M&S for Pediatric Drug Development: Regulatory Insights into Practical Issues
Found in Translation Building an Early Development Strategy for Complex Biologics
How Due Diligence Facilitates Successful Biotech Investments, Deals, and Partnerships
Application of Tracer Kinetics in Drug Development A Valuable but Underused Tool in Clinical Pharmac
A House Divided – The Interplay of Bioanalysis and Pharmacokinetics
Apocalyptic Clinical Pharmacology A Comprehensive Approach to Drug Development
Value Focused MIDD: Influenza Model-informed Drug Development Program
Value Focused MIDD: Respiratory Syncytial Virus (RSV) Model-informed Drug Development Program
Value Focused MIDD: Oncology Model-informed Drug Development Program
Town Level Agent Based Influenza Model
Influenza pandemic model of US
Best Practices in Clinical Pharmacology Gap Analysis
للحصول على شهادة
- 1-
التسجيل
- 2- مشاهدة الكورس كاملا
- 3- متابعة نسبة اكتمال الكورس تدريجيا
- 4- بعد الانتهاء تظهر الشهادة في الملف الشخصي الخاص بك